This article has been cited by
1Sex-gender-related therapeutic approaches for cardiovascular complications associated with diabetes
Ilaria Campesi,Flavia Franconi,Giuseppe Seghieri,Marco Meloni
Pharmacological Research.2017;119()195
[DOI]
2Metabolic effects of bile acid sequestration
Valeria Spinelli,Oscar Chávez-Talavera,Anne Tailleux,Bart Staels
Current Opinion in Endocrinology & Diabetes and Obesity.2016;23(2)138
[DOI]
3Gender differences in the effects of cardiovascular drugs
J Tamargo,G Rosano,T Walther,J Duarte,A Niessner,JC Kaski,C Ceconi,H Drexel,K Kjeldsen,G Savarese,C Torp-Pedersen,D Atar,BS Lewis,S Agewall
European Heart Journal - Cardiovascular Pharmacotherapy.2017;3(3)163
[DOI]
4Les médicaments cardiovasculaires qui favorisent le diabète
B. Vergès
Archives des Maladies du Coeur et des Vaisseaux - Pratique.2019;2019(274)20
[DOI]
5Drug-induced diabetes type 2: In silico study involving class B GPCRs
Dorota Latek,Ewelina Rutkowska,Szymon Niewieczerzal,Judyta Cielecka-Piontek,Arun Shukla
PLOS ONE.2019;14(1)e0208892
[DOI]
6Leptin and adiponectin DNA methylation levels in adipose tissues and blood cells are associated with BMI, waist girth and LDL-cholesterol levels in severely obese men and women
Andrée-Anne Houde,Cécilia Légaré,Simon Biron,Odette Lescelleur,Laurent Biertho,Simon Marceau,André Tchernof,Marie-Claude Vohl,Marie-France Hivert,Luigi Bouchard
BMC Medical Genetics.2015;16(1)e0208892
[DOI]
7Leptin and adiponectin DNA methylation levels in adipose tissues and blood cells are associated with BMI, waist girth and LDL-cholesterol levels in severely obese men and women
Mark A. Moyad
BMC Medical Genetics.2016;16(1)141
[DOI]
8Pharmacotherapy with Thymoquinone Improved Pancreatic ß-Cell Integrity and Functional Activity, Enhanced Islets Revascularization, and Alleviated Metabolic and Hepato-Renal Disturbances in Streptozotocin-Induced Diabetes in Rats
Adel Galal El-Shemi,Osama Adnan Kensara,Aiman Alsaegh,Mohammed Hasan Mukhtar
Pharmacology.2018;101(1-2)9
[DOI]
9Importancia de la dislipidemia en la enfermedad cardiovascular: un punto de vista
Juan F. Ascaso,Rafael Carmena
Clínica e Investigación en Arteriosclerosis.2015;27(6)301
[DOI]
10Statin use and reduced risk of biliary tract cancers in the UK Clinical Practice Research Datalink
Zhiwei Liu,Rotana Alsaggaf,Katherine A McGlynn,Lesley A Anderson,Huei-Ting Tsai,Bin Zhu,Yue Zhu,Sam M Mbulaiteye,Shahinaz M Gadalla,Jill Koshiol
Gut.2019;68(8)1458
[DOI]
11Statin-induced new onset of diabetes in dyslipidemic patients: a retrospective study
Roshna Roy,Architha Ajithan,Anisa Joseph,Uday Venkat Mateti,Subramanyam K
Postgraduate Medicine.2019;131(6)383
[DOI]
12Sex Differences in the Cardiovascular Consequences of Diabetes Mellitus
Judith G. Regensteiner,Sherita Golden,Amy G. Huebschmann,Elizabeth Barrett-Connor,Alice Y. Chang,Deborah Chyun,Caroline S. Fox,Catherine Kim,Nehal Mehta,Jane F. Reckelhoff,Jane E.B. Reusch,Kathryn M. Rexrode,Anne E. Sumner,Francine K. Welty,Nanette K. Wenger,Blair Anton
Circulation.2015;132(25)2424
[DOI]
13Statins Do Not Directly Inhibit the Activity of Major Epigenetic Modifying Enzymes
Stephanie Bridgeman,Wendy Northrop,Gaewyn Ellison,Thiru Sabapathy,Phillip E. Melton,Philip Newsholme,Cyril D. S. Mamotte
Cancers.2019;11(4)516
[DOI]
14Cardiovascular Disease in Women
Mariana Garcia,Sharon L. Mulvagh,C. Noel Bairey Merz,Julie E. Buring,JoAnn E. Manson
Circulation Research.2016;118(8)1273
[DOI]
15Toxicity of Atorvastatin on Pancreas Mitochondria: A Justification for Increased Risk of Diabetes Mellitus
Melina Sadighara,Zahra Amirsheardost,Mohsen Minaiyan,Valiollah Hajhashemi,Parvaneh Naserzadeh,Ahmad Salimi,Enayatollah Seydi,Jalal Pourahmad
Basic & Clinical Pharmacology & Toxicology.2017;120(2)131
[DOI]
16Examining prescriber perceptions of statin therapy and the potential implications these perceptions may have on guideline adherence
Emily Leppien,Tammie Lee Demler
International Clinical Psychopharmacology.2018;33(5)290
[DOI]
17Optimizing the Pharmacological Profile of New Bifunctional Antihyperlipidemic/Antioxidant Morpholine Derivatives
Alexios N. Matralis,Angeliki P. Kourounakis
ACS Medicinal Chemistry Letters.2019;10(1)98
[DOI]
18Coenzyme Q 10 protects against ß-cell toxicity induced by pravastatin treatment of hypercholesterolemia
Estela Lorza-Gil,Jane C. de Souza,Marta García-Arévalo,Jean F. Vettorazzi,Ana Carolina Marques,Alessandro G. Salerno,Jose Roberto Trigo,Helena C. F. Oliveira
Journal of Cellular Physiology.2019;234(7)11047
[DOI]
19Role of Statins in Glucose Homeostasis and Insulin Resistance
Chanukya Dahagam,Virginia S. Hahn,Aditya Goud,Jason D’Souza,Abdelhai Abdelqader,Roger S. Blumenthal,Seth S. Martin
Current Cardiovascular Risk Reports.2016;10(12)11047
[DOI]
20Complications of Diabetes
Konstantinos Papatheodorou,Maciej Banach,Michael Edmonds,Nikolaos Papanas,Dimitrios Papazoglou
Journal of Diabetes Research.2015;2015(12)1
[DOI]
21Statins and the potential for higher diabetes mellitus risk
Srikanth Yandrapalli,Aaqib Malik,Kenneth Guber,Yogitha Rochlani,Gayatri Pemmasani,Manasa Jasti,Wilbert S Aronow
Expert Review of Clinical Pharmacology.2019;12(9)825
[DOI]
22Novel insights into the pathophysiology and clinical aspects of diabetic nephropathy
Zubair Ilyas,Joumana T. Chaiban,Armand Krikorian
Reviews in Endocrine and Metabolic Disorders.2017;18(1)21
[DOI]
23Statin use in prediabetic patients: rationale and results to date
Anastazia Kei,Evangelos C. Rizos,Moses Elisaf
Therapeutic Advances in Chronic Disease.2015;6(5)246
[DOI]
24Vascular injury in diabetic db/db mice is ameliorated by atorvastatin: role of Rac1/2-sensitive Nox-dependent pathways
Thiago Bruder-Nascimento,Glaucia E. Callera,Augusto C. Montezano,Ying He,Tayze T. Antunes,Aurelie Nguyen Dinh Cat,Rita C. Tostes,Rhian M. Touyz
Clinical Science.2015;128(7)411
[DOI]
25Integrative roles of microRNAs in lipid metabolism and dyslipidemia
Leslie R. Sedgeman,Danielle L. Michell,Kasey C. Vickers
Current Opinion in Lipidology.2019;30(3)165
[DOI]
26Glycemic effects of simvastatin: Where do we stand?
Nor Razida Razali,Hasniza Zaman Huri,Luqman Ibrahim,Shireene Ratna Vethakkan,Bashar Mudhaffar Abdullah
Brazilian Journal of Pharmaceutical Sciences.2018;54(1)165
[DOI]
27STATIN ADVERSE EFFECTS: MECHANISMS, DIAGNOSIS, PREVENTION AND MANAGEMENT
A. I. Dyadyk,T. E. Kugler,Y. V. Suliman,S. R. Zborovskyy,I. I. Zdykhovskaya
The Russian Archives of Internal Medicine.2018;8(4)266
[DOI]
28Intestinal bile acid sequestration improves glucose control by stimulating hepatic miR-182-5p in type 2 diabetes
Leslie R. Sedgeman,Carine Beysen,Ryan M. Allen,Marisol A. Ramirez Solano,Scott M. Turner,Kasey C. Vickers
American Journal of Physiology-Gastrointestinal and Liver Physiology.2018;315(5)G810
[DOI]
29La diabetogenicidad de las estatinas: ¿son todas iguales? Estado de la cuestión
Joan Rius Tarruella,Jesús Millán Núñez-Cortés,Juan Pedro-Botet,Xavier Pintó Sala
Clínica e Investigación en Arteriosclerosis.2015;27(3)148
[DOI]
30Shared Genetic Contribution of Type 2 Diabetes and Cardiovascular Disease: Implications for Prognosis and Treatment
Rona J. Strawbridge,Natalie R. van Zuydam
Current Diabetes Reports.2018;18(8)148
[DOI]
  Feedback 
  Subscribe